Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.45 |
| ▸ | HTR1D | P28221 | 11/20 | 0.45 |
| ▸ | HTR1B | P28222 | 11/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25482345 | 0.90 | LRRK2 (0.43) | HTR1AHTR1DHTR1BLRRK2GABRA1 | |
| SCHEMBL25666759 | 0.90 | LRRK2 (0.44) | HTR1AHTR1DHTR1BLRRK2PDE10A | |
| SCHEMBL25819577 | 0.86 | HTR1A (0.41) | HTR1AHTR1DHTR1BGABRG2GABRB3 | |
| SCHEMBL25819437 | 0.85 | FFAR4 (0.39) | LRRK2PDE10A | |
| SCHEMBL25935366 | 0.85 | LRRK2 (0.46) | HTR1AHTR1DHTR1BLRRK2 | |
| SCHEMBL25819581 | 0.84 | MAPT (0.51) | — | |
| SCHEMBL25935028 | 0.84 | FFAR4 (0.49) | LRRK2PDE10A | |
| SCHEMBL25935109 | 0.83 | FFAR4 (0.50) | — | |
| SCHEMBL25482314 | 0.83 | DGAT1 (0.43) | LRRK2PDE10A | |
| SCHEMBL25935357 | 0.83 | ITGB2 (0.39) | LRRK2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | HTR1A 4156/4885HTR1D 4288/4885HTR1B 4222/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | HTR1A 2866/4885HTR1D 3081/4885HTR1B 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.